Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine combined with toripalimab for recurrent or refractory follicular lymphoma
ChiCTR2000031730Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and toripalimab in follicular lymphoma (FL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Routine blood, Liver and kidney function and 3 more. Started Apr 2020; status: recruiting.
02
Drugs
decitabinetoripalimab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2000031730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031730.